Eva B.
- Country
- Germany
- Department
- Lungenklinik Köln-Merheim
Research Overview
- Phase I/II Study on Safety, Tolerability, and Immunogenicity of PDC*lung01 with or without Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer Patients
- Efficacy and Safety Evaluation of Inupadenant Hydrochloride with Carboplatin and Pemetrexed in Metastatic Nonsquamous Non-Small Cell Lung Cancer Post-Immunotherapy
- Efficacy and Safety of Durvalumab with Cisplatin/Carboplatin and Etoposide Plus Radiotherapy in Limited Disease Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 7 of 59 partner sites.
Specializations
Non-Small Cell Lung Cancer (NSCLC)
This investigator specializes in studying advanced treatment approaches for non-small cell lung cancer, with particular focus on both early-stage and metastatic disease management.
- Resectable NSCLC Stage IIA to IIIB
- EGFR-mutated NSCLC
- KRAS G12C-positive advanced NSCLC
Their research encompasses novel therapeutic combinations including immunotherapy, targeted therapies, and conventional chemotherapy protocols.
Small Cell Lung Cancer (SCLC)
The investigator conducts research in limited-stage small cell lung cancer treatment strategies, focusing on innovative therapeutic approaches.
- Limited Disease SCLC
- Extensive-Stage SCLC
- Combination Immunotherapy Approaches
Their work includes evaluation of immunotherapy combinations with standard chemoradiation therapy protocols.
Specialized Treatment Modalities
The investigator explores various therapeutic strategies including neoadjuvant treatment and adjuvant therapy approaches.
- Immunotherapy Combinations
- Targeted Molecular Therapies
- Multimodal Treatment Approaches
Their research includes investigation of novel drug combinations and treatment sequences for optimal patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.